Bluebird Bio (BLUE)

$4.97 +0.23 (4.85%)
Market Cap 48.67M
Revenue (ttm) 83.81M
Net Income (ttm) -240.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -287.22%
Debt to Equity Ratio -2.02
Volume 1,245,100
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 9.79M
Stochastic %K N/A
Beta 0.27
Analysts Hold
Price Target $9.33

Company Profile

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cereb...

Industry: Biotechnology
Sector: Healthcare
Phone: 339 499 9300
Address:
455 Grand Union Boulevard, Somerville, United States
I_am_Sparta
I_am_Sparta Dec. 3 at 4:50 PM
$IOVA greatest criminal Bio STONK ever.... more criminal like $BLUE ..... hope shorts destroy this Fred face SUCKER
3 · Reply
gargoyl
gargoyl Nov. 26 at 3:46 PM
$BLUE Any progress 👇🏼 The CVR paid $6.84 per CVR (i.e. per share) if bluebird’s current product portfolio achieved $600 million in net sales in any trailing 12-month period on or before December 31, 2027. • That structure produced a potential total of $9.84 per share if the milestone were hit (subject to the CVR conditions, tender/closing conditions, regulatory approvals, etc.
1 · Reply
Obiwan123
Obiwan123 Nov. 26 at 4:11 AM
$BLUE blue mgmt really destroyed this company and its shareholders. even if it was struggling they give themselves equity incentive. what a pile manure thr mgmt was?
0 · Reply
Obiwan123
Obiwan123 Nov. 22 at 12:44 AM
$BLUE so did blue win thr patent case against san rocco?. all thst fiasco only to bring down bluebird. damn worst investment I made.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Nov. 4 at 1:09 PM
$ONCY is Turning Viruses into Cancer Killers 🧬 Oncolytics Biotech is a clinical stage company advancing pelareorep, an intravenously delivered oncolytic virus designed to selectively kill cancer cells and stimulate an anti-tumor immune response. Latest Update: Pelareorep combined with atezolizumab achieved a 30% objective response rate in advanced anal cancer which is more than double the current standard of care. Upcoming Catalysts: ✅ FDA discussion on an accelerated-approval pathway in anal cancer ✅ Regulatory alignment for a pancreatic cancer registration strategy ✅ Additional GOBLET trial data readouts across GI cancer cohorts ✅ Launch and updates from the breast cancer registration-enabling trial ✅ Potential partnership or financing news to support late-stage. With data momentum, leadership depth, and a $258 billion market ahead, Oncolytics may be on the verge of translating science into scale. Communicated Disclaimer: http://bit.ly/4qzOlZb Sector Peers: $CRSP $NTLA $EDIT $BLUE
1 · Reply
MF__DOOM
MF__DOOM Nov. 3 at 3:58 PM
$QURE I have yet to call a bo and a bo not happen I’m about 20 out of 20 correct now But I’ll give warning I said BO for $BLUE and we ended up getting the worst bo in history so let’s hope this stock doesn’t get that fate too $SPY $QQQ $XBI
0 · Reply
MF__DOOM
MF__DOOM Nov. 1 at 6:50 PM
$QURE $BLUE $SPY $QQQ never forget
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Oct. 30 at 2:51 AM
$BLUE $JAY.X $ETH.X
0 · Reply
Leemarvin70
Leemarvin70 Oct. 10 at 10:39 AM
$BHAT $BLUE Aquí tenemos los resultados de tomar una medicación sin receta.
0 · Reply
Brooklynmess22
Brooklynmess22 Oct. 9 at 3:22 PM
$BHAT $BLUE
3 · Reply
Latest News on BLUE
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots

Sep 18, 2025, 8:00 AM EDT - 2 months ago

bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots

bluebird bio Strengthens Leadership Team With New Appointments

Jul 1, 2025, 9:00 AM EDT - 5 months ago

bluebird bio Strengthens Leadership Team With New Appointments

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

Jun 2, 2025, 8:34 AM EDT - 6 months ago

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

CG

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

May 30, 2025, 8:30 AM EDT - 6 months ago

Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

CG

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

May 27, 2025, 8:30 AM EDT - 7 months ago

bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

May 16, 2025, 4:30 PM EDT - 7 months ago

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

CG

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital

May 14, 2025, 8:52 AM EDT - 7 months ago

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital

CG

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

May 14, 2025, 8:30 AM EDT - 7 months ago

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

CG

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

May 9, 2025, 8:30 AM EDT - 7 months ago

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

May 5, 2025, 4:00 PM EDT - 7 months ago

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

CG

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Apr 16, 2025, 8:00 AM EDT - 8 months ago

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Mar 31, 2025, 11:24 AM EDT - 9 months ago

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Bluebird bio receives non-binding bid for up to $110.5 million

Mar 28, 2025, 5:43 PM EDT - 9 months ago

Bluebird bio receives non-binding bid for up to $110.5 million

Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update

Mar 28, 2025, 5:06 PM EDT - 9 months ago

Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Mar 28, 2025, 4:15 PM EDT - 9 months ago

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

Mar 13, 2025, 3:43 PM EDT - 9 months ago

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

Feb 21, 2025, 3:43 PM EST - 10 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

CG

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Feb 21, 2025, 1:48 PM EST - 10 months ago

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs

Feb 21, 2025, 9:45 AM EST - 10 months ago

bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs

CG

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

Feb 21, 2025, 8:04 AM EST - 10 months ago

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

CG

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

Feb 21, 2025, 7:30 AM EST - 10 months ago

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

CG

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

Feb 18, 2025, 9:52 AM EST - 10 months ago

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

CVS VRTX

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 8, 2024, 12:30 PM EST - 1 year ago

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Dec 7, 2024, 12:00 PM EST - 1 year ago

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio Announces 1-for-20 Reverse Stock Split

Dec 4, 2024, 4:05 PM EST - 1 year ago

bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Dec 4, 2024, 8:47 AM EST - 1 year ago

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

FDA investigates risk of blood cancers from bluebird bio's gene therapy

Nov 27, 2024, 11:45 AM EST - 1 year ago

FDA investigates risk of blood cancers from bluebird bio's gene therapy

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

Nov 20, 2024, 8:10 AM EST - 1 year ago

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

AAPL ABBV AGNC AM ARCC ARI AVGO

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

Nov 15, 2024, 2:05 PM EST - 1 year ago

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:06 AM EST - 1 year ago

bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Nov 14, 2024, 7:00 AM EST - 1 year ago

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

Nov 6, 2024, 4:15 PM EST - 1 year ago

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:05 AM EST - 1 year ago

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Bluebird Bio (BLUE) Stock Dips Amid Market Volatility

Oct 8, 2024, 3:53 PM EDT - 1 year ago

Bluebird Bio (BLUE) Stock Dips Amid Market Volatility

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BMY CRSP EDIT EXAS NTLA

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 4, 2024, 4:05 PM EDT - 1 year ago

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Sep 27, 2024, 4:30 PM EDT - 1 year ago

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Bluebird bio to cut 25% of workforce as part of restructuring

Sep 24, 2024, 7:08 AM EDT - 1 year ago

Bluebird bio to cut 25% of workforce as part of restructuring

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Sep 24, 2024, 7:00 AM EDT - 1 year ago

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Sep 13, 2024, 4:41 PM EDT - 1 year ago

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys

Aug 28, 2024, 8:10 AM EDT - 1 year ago

My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys

AAPL ABBV AGNC AM APLE ARCC ARI

bluebird bio Announces September Investor Events

Aug 28, 2024, 8:00 AM EDT - 1 year ago

bluebird bio Announces September Investor Events

bluebird bio Announces Receipt of Expected Notices from Nasdaq

Aug 23, 2024, 4:05 PM EDT - 1 year ago

bluebird bio Announces Receipt of Expected Notices from Nasdaq

I_am_Sparta
I_am_Sparta Dec. 3 at 4:50 PM
$IOVA greatest criminal Bio STONK ever.... more criminal like $BLUE ..... hope shorts destroy this Fred face SUCKER
3 · Reply
gargoyl
gargoyl Nov. 26 at 3:46 PM
$BLUE Any progress 👇🏼 The CVR paid $6.84 per CVR (i.e. per share) if bluebird’s current product portfolio achieved $600 million in net sales in any trailing 12-month period on or before December 31, 2027. • That structure produced a potential total of $9.84 per share if the milestone were hit (subject to the CVR conditions, tender/closing conditions, regulatory approvals, etc.
1 · Reply
Obiwan123
Obiwan123 Nov. 26 at 4:11 AM
$BLUE blue mgmt really destroyed this company and its shareholders. even if it was struggling they give themselves equity incentive. what a pile manure thr mgmt was?
0 · Reply
Obiwan123
Obiwan123 Nov. 22 at 12:44 AM
$BLUE so did blue win thr patent case against san rocco?. all thst fiasco only to bring down bluebird. damn worst investment I made.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Nov. 4 at 1:09 PM
$ONCY is Turning Viruses into Cancer Killers 🧬 Oncolytics Biotech is a clinical stage company advancing pelareorep, an intravenously delivered oncolytic virus designed to selectively kill cancer cells and stimulate an anti-tumor immune response. Latest Update: Pelareorep combined with atezolizumab achieved a 30% objective response rate in advanced anal cancer which is more than double the current standard of care. Upcoming Catalysts: ✅ FDA discussion on an accelerated-approval pathway in anal cancer ✅ Regulatory alignment for a pancreatic cancer registration strategy ✅ Additional GOBLET trial data readouts across GI cancer cohorts ✅ Launch and updates from the breast cancer registration-enabling trial ✅ Potential partnership or financing news to support late-stage. With data momentum, leadership depth, and a $258 billion market ahead, Oncolytics may be on the verge of translating science into scale. Communicated Disclaimer: http://bit.ly/4qzOlZb Sector Peers: $CRSP $NTLA $EDIT $BLUE
1 · Reply
MF__DOOM
MF__DOOM Nov. 3 at 3:58 PM
$QURE I have yet to call a bo and a bo not happen I’m about 20 out of 20 correct now But I’ll give warning I said BO for $BLUE and we ended up getting the worst bo in history so let’s hope this stock doesn’t get that fate too $SPY $QQQ $XBI
0 · Reply
MF__DOOM
MF__DOOM Nov. 1 at 6:50 PM
$QURE $BLUE $SPY $QQQ never forget
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Oct. 30 at 2:51 AM
$BLUE $JAY.X $ETH.X
0 · Reply
Leemarvin70
Leemarvin70 Oct. 10 at 10:39 AM
$BHAT $BLUE Aquí tenemos los resultados de tomar una medicación sin receta.
0 · Reply
Brooklynmess22
Brooklynmess22 Oct. 9 at 3:22 PM
$BHAT $BLUE
3 · Reply
Brooklynmess22
Brooklynmess22 Oct. 7 at 7:18 PM
$BHAT $BLUE Hat Interactive Entmt Tec 1000 kg of gold =1 ton should be a $120 million market cap 🚨🚨💰💰🍻😁🤯👀🤝🚀 plus shorts covering 750k shares and gold rally plus a squeeze would put this at $30-50 ez with people chasing the bag 💰
2 · Reply
BigBenBroke
BigBenBroke Sep. 27 at 1:39 AM
$BLUE what happens to my blue share. Now I see no value to account. ?
1 · Reply
IAMARICHMAN
IAMARICHMAN Sep. 25 at 7:45 PM
$BLUE WHY CAN'T I FIND BLUE STOCK ANYMORE ON ROBINHOOD?
1 · Reply
Stock1701
Stock1701 Sep. 25 at 2:15 PM
$IOVA It might seem similar to $BLUE but it really isn’t.
2 · Reply
MF__DOOM
MF__DOOM Sep. 24 at 4:15 PM
$QURE $80-100 buyout said it years ago $SPY $QQQ wish that $BLUE had gotten the same treatment
0 · Reply
Obiwan123
Obiwan123 Sep. 22 at 4:48 PM
$BLUE has a new name: https://www.genetixbiotx.com/#team the company that destroyed most of its shareholders. bluebird bio mgmt were full of liars!!!!
1 · Reply
gargoyl
gargoyl Sep. 12 at 5:45 AM
$BLRX $BLUE Gamida Cell Arymid BlackRock PDAC SCD Aphreses Motixafortide APHEXDA Kreos Capital
0 · Reply
gargoyl
gargoyl Sep. 12 at 5:17 AM
$BLRX 🗡️ $BLUE 🤔
1 · Reply
gargoyl
gargoyl Sep. 12 at 5:15 AM
$BLRX ⚔️ $BLUE
0 · Reply
gargoyl
gargoyl Sep. 12 at 5:12 AM
$BLRX ⚔️ $BLUE 🤔
0 · Reply
stu4
stu4 Sep. 8 at 1:05 PM
$AGIO can I lead you to water ???? Sure Will you drink it …obviously not !!! Someone gave you bad info…. Now for the real deal…do some homework on: HIM ….( then come back and post , nonsense ) This brain power and CEO stewardship doesn’t, and never did exist here or at $NTLA $CADL $BLUE $DCPH
0 · Reply
Letsinvest2024
Letsinvest2024 Sep. 5 at 5:24 PM
$BLUE where is my CVR payment?
1 · Reply